KRAS and neoplasm: By obtaining tumor-derived material from peripheral blood of PDAC patients, genetic alterations (e.g., KRAS) reflecting tumor heterogeneity were identified in circulating tumor DNA (ctDNA), while analysis of circulating tumor cells (CTCs) and ctDNA showed potential for monitoring treatment outcome and disease progression (reviewed in [16,18,19]).